Benztropine (Cogentin®) is a medication used to treat the symptoms of Parkinson’s disease and other disorders involving muscle stiffness or spasms. Benztropine is a synthetic anticholinergic drug, meaning it blocks the action of a neurotransmitter called acetylcholine. This helps reduce muscle stiffness and spasms, allowing for improved movement.

Benztropine has been used to treat Parkinson’s disease since the 1960s. It is often prescribed in combination with levodopa and other drugs to manage the motor symptoms of the disease. In addition, benztropine has been used to treat certain types of tremors, dystonia, and tardive dyskinesia. It is also used to treat the side effects of antipsychotic medications, including dry mouth, constipation, and blurred vision.

Benztropine is usually taken orally, either as a tablet or liquid suspension. It is rapidly absorbed into the bloodstream, and its effects begin within one hour. The peak effect is typically reached within two to four hours, and the effects usually last for 6-8 hours. The dosage of benztropine is typically started low, and gradually increased until the desired effect is achieved.

Common side effects of benztropine include dry mouth, constipation, blurred vision, dizziness, and drowsiness. More serious side effects can include confusion, difficulty urinating, and changes in heart rate or blood pressure. People taking benztropine should not consume alcohol, as it can increase the risk of side effects. Additionally, benztropine can interact with some other medications, so it is important to tell your doctor about any other medications you are taking.

Benztropine is a valuable tool in managing the symptoms of Parkinson’s disease and other disorders involving muscle stiffness or spasms. While it is generally safe and effective, it can have serious side effects, so it should be used with caution and only under the supervision of a doctor.


Cogentin® (benztropine mesylate) [Package insert]. (2020). West-Ward Pharmaceuticals.

Koller, W. C., & Vetere-Overfield, B. (2009). Parkinson’s disease: Diagnosis and clinical management. London, UK: Informa Healthcare.

Mateo, Y. (2017). Anticholinergics in Parkinson’s disease. In M. Y. M. Simuni & C. R. Tilley (Eds.), The Treatment of Parkinson’s Disease (3rd ed., pp. 99-117). New York, NY: Springer.

Pahwa, R., Lyons, K. E., & Koller, W. C. (2007). Treatment of Parkinson’s disease. Journal of the American Medical Association, 298(18), 2154-2164.

Wong, A., & Jankovic, J. (2015). Use of anticholinergics for the treatment of Parkinson’s disease. Movement Disorders, 30(4), 456-465.

Scroll to Top